Overview

Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease

Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is a safety and tolerability study investigating the effect of HPP854 in subjects with mild cognitive impairment or a diagnosis of mild Alzheimer's disease. The study will assess the pharmacokinetic and pharmacodynamic relationships of HPP854 in plasma, pharmacodynamic relationship in cerebral spinal fluid and plasma concentration profiles for Amyloid-Beta.
Phase:
Phase 1
Details
Lead Sponsor:
High Point Pharmaceuticals, LLC.